Chondroitin slows progression and relieves symptoms of knee osteoarthritis

Jan 29, 2009

Osteoarthritis (OA) causes disability and is a major public health problem. A new study examined the effect of chondroitins 4 and 6 sulfate (CS) on OA progression and symptoms. CS, unlike other chondroitin sulfate products sold as dietary supplements in the U.S., has been approved as a prescription symptomatic slow acting drug for OA in many European countries. The study was published in the February issue of Arthritis & Rheumatism.

Led by Andre Kahan of the University of Paris Descartes in Paris, the randomized, double-blind, placebo-controlled study involved 622 patients with OA from France, Belgium, Switzerland, Austria and the U.S. Patients had knee X-rays at the time of enrollment and at 12, 18 and 24 months. The X-rays were evaluated for joint space loss and patients were also assessed for OA symptoms and pain.

The results showed that "long-term administration of CS over 2 years can prevent joint structure degradation in patients with knee OA," the authors state. Joint space loss was significantly reduced in the CS group, fewer patients had progression of joint space width, and CS reduced pain in those taking it compared to the placebo group. CS was well-tolerated and there were no significant differences in the frequency of adverse events between the two groups.

The study showed that there was faster improvement regarding pain during the first year in the CS group compared to the placebo group. This may be due to the fact that all of the patients had pain symptoms, so the effect of CS was more noticeable early on. Since those who took a placebo also had decreased pain in the first year, it may also be due to the natural course of the disease. The authors note that the study involved CS, which is used as a prescription drug and that the results cannot be generalized to other chondroitin sulfate products or compounds, such as those available in the form of dietary supplements.

The decrease in joint space loss shown in this and another recent study involving 300 patients, suggests better outcomes for OA patients, according to the authors. They conclude: "Further studies with longer followup and different outcome criteria are warranted to assess whether the beneficial structural changes associated with CS demonstrated in our study are predictive of improvement in the long-term clinical progression of OA."

Journal: www3.interscience.wiley.com/journal/76509746/home

Source: Wiley

Explore further: Biomarker for fatty liver disease

add to favorites email to friend print save as pdf

Related Stories

China's latest survey finds increase in wild giant pandas

23 hours ago

(AP)—Wild giant pandas in China are doing well. According to a census by China's State Forestry Administration, the panda population has grown by 268 to a total of 1,864 since the last survey ending in ...

Korean tech start-ups offer life beyond Samsung

Feb 23, 2015

As an engineering major at Seoul's Yonsei University, Yoon Ja-Young was perfectly poised to follow the secure, lucrative and socially prized career path long-favoured by South Korea's elite graduates.

Fresh nuclear leak detected at Fukushima plant

Feb 22, 2015

Sensors at the Fukushima nuclear plant have detected a fresh leak of highly radioactive water to the sea, the plant's operator announced Sunday, highlighting difficulties in decommissioning the crippled plant.

Recommended for you

Biomarker for fatty liver disease

1 hour ago

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent ...

Liberia's last Ebola patient discharged

4 hours ago

Liberia discharged its last confirmed Ebola patient on Thursday, as it reported for the first time in nine months it had gone a full week without any new infections.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

VOR
not rated yet Jan 30, 2009
"CS, unlike other chondroitin sulfate products sold as dietary supplements in the U.S., has been approved as a prescription symptomatic slow acting drug for OA in many European countries" .... I'm confused by the wording 'CS, unlike other chondroitin sufate products'... this implies it is different and unique, but I dont think thats what they mean to say.. very confusing! is it unique chemically or only unique in that its approved? anyone know? I think its the latter but its written so poorly I cant be sure.
VOR
not rated yet Feb 01, 2009
this helps clarify: http://www.nutrai...on-Study

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.